The work presents the design of an integrated system consisting of a high-pressure electroosmotic (EO) micropump and a microporous monolithic emitter, which together generate a stable and robust electrospray. Both the micropump and electrospray emitter are fabricated using a sol-gel process. Upon application of an electric potential of sufficient amplitude (>2 kV), the pump delivers fluids with...

Electric field distribution and field emission current over the surface of point (sphere-on-cone) and wedge-shaped defects on a plane substrate are studied. It is found emission current due to wedge-shaped defects is more sensitive to emitter-anode distance than in case of point conical defects. This property is consequence of greater emission area of wedge-shaped defects and has important prac...

This paper presents a systematic parameter extraction method for an HBT temperature-dependant equivalent-circuit DC model. A reliable procedure was developed for determining the HBT thermal resistance, requiring only forward Gummel data at different temperatures and collector-emitter bias voltages. The extraction method was applied to predict the DC characteristics of a 2x25 μm emitter-area InG...

Triplet emitter materials present attractive possibilities for optimizations of organic/organometallic light emitting diodes (OLEDs). This is due to the significantly higher efficiencies obtainable with these compounds as compared to organic emitters. In this contribution, first a schematic introduction is given, how an OLED device is built-up and why multi-layer structures are preferred. Then ...

background and objective: the most common intravascular brachytherapy sources include 32p, 188re, 106rh and 90sr/90y. in this research, skin absorbed dose for different covering materials in dealing with these sources were evaluated and the best covering material for skin protection and reduction of absorbed dose by radiation staff was recognized and recommended. method: four materials includin...

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...